Insulin-mediated regulation of the endothelial renin–angiotensin system and vascular cell growth

Objective Insulin has a growth-stimulating effect for vascular tissue. At the tissue level, the vascular renin–angiotensin system (RAS) may be involved in the progression of atherosclerosis or vascular hypertrophy. We previously reported that the vascular RAS activity is activated in vascular smooth muscle cells (SMC) by insulin stimulation. However, the effect of insulin on the RAS in endothelial cells (EC) is not fully understood. Methods Cultured human EC were incubated with or without insulin. After incubation for 48 h, cellular angiotensinogen and renin mRNA expression and levels in the cells were quantified by slot-blot hybridization and radioimmunoassay. Angiotensin I converting enzyme (ACE) activity in EC homogenates was measured by modified Cushman and Cheung method. EC growth and SMC with or without EC using co-culture were assessed by 3H-thymidine uptake for evaluation of their growth. Results All doses of insulin (10, 100, 1000 μU/ml) decreased angiotensinogen and renin mRNA expression (angiotensinogen: 19.3%, P < 0.05; 25.4%, P < 0.01; 26.2%, P < 0.01, renin: 12.9%, P < 0.05; 21.3%, P < 0.01; 14.3%, P < 0.05, respectively). Both cellular angiotensinogen and renin level were also reduced by high levels of insulin. Neither 10 nor 100 μU/ml insulin increased cellular angiotensin converting enzyme (ACE) activity (2.17 to 3.48-folds, P = 0.077, 0.125, respectively) significantly, but 1000 μU/ml insulin strongly up-regulated ACE activity by 16.67-folds (P = 0.001) in cultured EC. For the co-culture with EC and SMC, 100 μU/ml insulin was not able to induce SMC but 1000 μU/ml insulin accelerated SMC growth in the co-culture. In contrast insulin that was over 100 μU/ml induced SMC growth in the sole culture of SMC. Conclusion Either low or high levels of insulin suppressed angiotensinogen and renin expression, however, high doses of insulin stimulated ACE activity in cultured human aortic EC. This may indicate that insulin regulates vascular cell growth and endothelial function via bifunctional modification of the vascular angiotensin generation.

[1]  T. Ogihara,et al.  Role of endothelin-1 induced by insulin in the regulation of vascular cell growth. , 2003, American journal of hypertension.

[2]  T. Ogihara,et al.  [Role of angiotensin in the metabolic syndrome and cardiovascular complications]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[3]  P. Poredos,et al.  Endothelial dysfunction in the pathogenesis of atherosclerosis. , 2002, International angiology : a journal of the International Union of Angiology.

[4]  K. Egashira Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[5]  T. Ogihara,et al.  Vascular signaling pathways in the metabolic syndrome , 2002, Current hypertension reports.

[6]  K. Kamide,et al.  Insulin and insulin‐like growth factor‐I promotes angiotensinogen production and growth in vascular smooth muscle cells , 2000, Journal of hypertension.

[7]  G. King,et al.  Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. , 2000, Circulation.

[8]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[9]  K. Kamide,et al.  Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. , 1998, Hypertension.

[10]  C. Kahn,et al.  Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. , 1997, The Journal of clinical investigation.

[11]  T. Ogihara,et al.  Insulin resistance is related to silent cerebral infarction in patients with essential hypertension. , 1997, American journal of hypertension.

[12]  T. Ogihara,et al.  Insulin resistance and cardiovascular complications in patients with essential hypertension. , 1996, American journal of hypertension.

[13]  T. Ogihara,et al.  Impaired endothelial function with essential hypertension assessed by ultrasonography. , 1996, American heart journal.

[14]  G. Dagenais,et al.  Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.

[15]  G M Steil,et al.  Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-mediated process. , 1996, The Journal of clinical investigation.

[16]  G. Reaven,et al.  Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. , 1996, The New England journal of medicine.

[17]  Y. Miyazaki,et al.  Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. , 1995, American journal of hypertension.

[18]  H. Cheung,et al.  Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca. , 1973, Biochimica et biophysica acta.

[19]  E. Nabel,et al.  Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury. , 1995, The Journal of clinical investigation.

[20]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .